A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
Phase of Trial: Phase III
Latest Information Update: 18 Jun 2019
Price : $35 *
At a glance
- Drugs Cinacalcet (Primary)
- Indications Renal failure; Secondary hyperparathyroidism
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 28 Jul 2016 This trial was completed in Greece (end date: 2016-06-23).
- 21 Jul 2016 This trial was completed in Slovakia (end date: 23-06-2016), according to European Clinical Trials Database.